Plain-English translation of NCT05033392 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing toripalimab, an immune-boosting medication, combined with chemotherapy to treat stomach cancer and gastroesophageal junction cancer before surgery. The study wants to see if this combination helps shrink tumors enough to make surgery more effective and improve long-term survival. You would receive the medication and chemotherapy together, have surgery, and then receive more treatment afterward.
Stomach cancer is often diagnosed at advanced stages when it's harder to treat. This trial exists to see whether adding an immune-boosting medication to standard chemotherapy before surgery can help more patients achieve complete remission and live longer.
You likely qualify if…
You likely don't qualify if…
You would receive intravenous infusions of the medication combined with chemotherapy every 2 weeks for four cycles (about 8 weeks total). After that, doctors will evaluate how well the treatment worked, and you'll have surgery within 4 weeks. Following surgery, you'll receive four more cycles of the same medication and chemotherapy combination. Throughout the trial, you'll have regular blood tests, imaging scans, and clinic visits to monitor your health and how you're responding to treatment.
AI-generated summary from trial data · Aug 2, 2026 · Not medical advice
China